Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
January 02, 2018 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today interim data from the first 14 patients that completed, to date, the...
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
December 27, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
November 29, 2017 07:55 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the completion of enrollment in the Company’s phase II clinical...
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
November 27, 2017 07:00 ET
|
Protalix BioTherapeutics, Inc.
Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of...
Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference
November 20, 2017 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical...
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
November 13, 2017 07:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update
November 08, 2017 07:00 ET
|
Protalix BioTherapeutics, Inc.
Collaboration Agreement with Chiesi Farmaceutici Further Validates Fabry Program and Significantly Improves Financial Position Sufficient Capital Resources to Fund Operations into 2020 Balance...
Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Corporate Update Conference Call on November 8, 2017
October 31, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
October 18, 2017 06:50 ET
|
Protalix BioTherapeutics, Inc.
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million upfront, an additional up to $25...
Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization...